CHICAGO, Jan. 3 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation, today announced that it will present and participate in a panel discussion during a special session of the of 26th Annual JPMorgan Healthcare Conference on January 9, 2008.
The Company's presentation will be delivered during a special
Biodefense Session hosted by JPMorgan and McKenna Long & Aldridge at 5:00
pm Pacific Time in the St. Francis Suite on the 12th floor of the Westin
St. Francis hotel in San Francisco, CA. The presentation will focus on the
Company's pre-NDA antibiotic, cethromycin, and its application as a
biodefense countermeasure. The panel will discuss public health
The program includes co-keynote addresses by:
-- Dr. Rajeev Venkeyya, Special Assistant to the President and Senior
Director for Biodefense at the White House Homeland Security Council
-- Brian Kamoie, Deputy Assistant Secretary Director, Office of Policy,
Strategic Planning & Communications Office of the Assistant Secretary
for Preparedness and Response U.S. Department of Health & Human
Following the Company's presentation and participation on the biodefense panel, there will be a question and answer session led by the moderator with audience participation.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections such as community acquired pneumonia (CAP). In addition to its utility in CAP, cethromycin is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has designated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other indication. For more information, please visit us on the web at http://www.advancedlifesciences.com.
Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
|SOURCE Advanced Life Sciences Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved